Zonagen seeks shareholder approval to change name to Repros Therapeutics Inc.

By E. Janene Geiss

Philadelphia, Feb. 8 - Zonagen, Inc. said Wednesday the company is seeking stockholder approval at its annual meeting to change the company's name to Repros Therapeutics Inc. to more accurately reflect its focus on therapeutics for reproductive disorders.

The 2006 annual meeting of stockholders is scheduled for noon May 2, according to a company news release.

The company said it will mail notices, a proxy statement and a form of proxy to stockholders of record about one month prior to the meeting. The record date for the meeting will be March 10, officials said.

"Our company was founded to commercialize technology originated at Baylor College of Medicine focusing on the reproductive system, and our name Zonagen reflected that focus. With our new focus on the development of drugs to treat hormonal and reproductive system disorders, we feel that the name Repros Therapeutics Inc. better reflects our new strategic focus," Joseph S. Podolski, president and chief executive officer, said in the release.

"We continue to make advances in the development of Proellex for the treatment of uterine fibroids and endometriosis, and Androxal for the treatment of testosterone deficiency in men. We urge our shareholders to vote in favor of this change in corporate identity and look forward to continued progress," Podolski added in the release.

Zonagen, based in The Woodlands, Texas, is a clinical stage biopharmaceutical company engaged in the development of new drugs to treat hormonal and reproductive system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.